What Can You Expect at Europe’s Definitive Induced Proximity Summit in 2027?
The 7th TPD & Induced Proximity Summit Europe returns to London, bringing together the scientists, innovators and decision-makers advancing the next generation of induced proximity therapies. As the field continues to expand beyond traditional degradation approaches, the meeting will explore the discoveries, technologies and strategies shaping future therapeutic opportunities.
Designed for a focused audience of 90+ leaders across biology, chemistry and R&D, the summit provides a platform for in-depth discussion around emerging mechanisms, rational drug design, novel target classes and investment priorities. You will gain direct insight into the scientific and commercial factors influencing the progression of the field across Europe.
More than just a scientific conference, the summit offers extensive opportunities to connect with peers, collaborators and industry pioneers. By combining cutting-edge science with meaningful networking, the event will help you identify new opportunities, build strategic partnerships and accelerate the development of induced proximity therapeutics towards patient impact.
Unmissable Event Highlights
Build Out the E3 Ligase Toolbox
Harness the full potential of cereblon and validate novel ligases to improve selectivity and unlock previously inaccessible targets.
Expert insights from:
- Tim Barrett, Director, Medicinal Chemistry, GSK
- Christian Steinebach, Professor, University of Greifswald
Explore Emerging Induced Proximity Mechanisms
Broaden the therapeutic reach of induced proximity through emerging modalities, including extracellular degraders, antibody-based degraders and non-degrading approaches.
Expert insights from:
- Stephen Myatt, Chief Executive Officer, Macomics
- Maureen Spit, Vice President, Research, Laigo Bio
Expand the Druggable Proteome
Validate and drug high-value targets across oncology and beyond to unlock new therapeutic possibilities, address unmet medical need and differentiate pipelines.
Expert insight from:
- Giovanni Spagnolli, Chief Technology Officer, Sibylla Biotech
- Paola Martinelli, Associate Director, Boehringer Ingelheim
Advance Rational Drug Design
Employ next-generation libraries, screening platforms and structural and computational tools to drive predictable induced proximity discovery.
Expert insight from:
- Chris Tame, Chief Executive Officer, Ternary Therapeutics
- James Lynch, Director, Oncology, Amphista Therapeutics
De-risk Induced Proximity Pipelines
Streamline development with advanced ADME, PK/PD and safety assessment strategies to strengthen translational confidence and support future investment.
Expert insight from:
- Emanuela Cuomo, Executive Director, Global Head Discovery Pharmacology, Merck KGaA
- Sophie Regan, Associate Director, AstraZeneca
What’s New for 2027?
12 New Speaking Companies & Academic Organisations
Uncover Novel Induced Proximity Mechanisms
“Rewiring Transcriptional Circuits through Induced Proximity”
- Christian Steinebach, Professor, University of Greifswald
“Deg-Mac: Next Generation Extracellular Protein Degraders”
- Stephen Myatt, Chief Executive Officer, Macomics
“Selective Blocking of the Sec61 Translocon: An Alternative Strategy for Targeted Protein Degradation”
- Yvonne McGrath, Chief Scientific Officer, Enodia Therapeutics
Dedicated Discovery, Preclinical and Translational Focus with Comprehensive Coverage of:
- Screening Tools & Libraries
- Rational Design Strategies
- Computational & Structural Tools for Mapping Ternary Complexes
- Expanding the Ligase Toolbox & Leveraging the Full Potential of Cereblon
- Optimizing Drug-Like Properties for Degraders
- Novel Degradation Mechanisms
- Non-Degrading Modalities
- PKPD Modelling
- Safety Assessments
- Attracting Investment & Partnership
Attending Companies Include
Explore the Full Event Guide
- Discovery & Preclinical Breakthroughs Across Glues, Heterobifunctionals, Novel Degraders & Non-Degrading Mechanisms
- Deep-Dive, Discussion-Led Workshops on Expanding the Ligase Toolbox & Predicting Degradation
- Data-Led Presentations from 6 Brand New Academic Innovators
- 5 Brand New Biotech Companies Taking to the Stage for the First Time
Explore the Agenda
Discover three days of content spanning PROTACs, glues, antibody-based degradation and non-degrading mechanisms.
Partner With Us
Elevate your brand and showcase your solutions to a world-class audience of induced proximity drug developers.
Join Biopharma Experts
Uniting large pharma experts, C-Level biotech leaders and KOLs, this forum is designed to foster vital industry connections.